SE0002354D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE0002354D0
SE0002354D0 SE0002354A SE0002354A SE0002354D0 SE 0002354 D0 SE0002354 D0 SE 0002354D0 SE 0002354 A SE0002354 A SE 0002354A SE 0002354 A SE0002354 A SE 0002354A SE 0002354 D0 SE0002354 D0 SE 0002354D0
Authority
SE
Sweden
Prior art keywords
treatment
new formulation
formulations
betablocker
atherosclerosis
Prior art date
Application number
SE0002354A
Other languages
English (en)
Swedish (sv)
Inventor
Goeran Berglund
John Wikstrand
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0002354A priority Critical patent/SE0002354D0/xx
Publication of SE0002354D0 publication Critical patent/SE0002354D0/xx
Priority to ARP010102759A priority patent/AR028699A1/es
Priority to EP01941409A priority patent/EP1296716B1/fr
Priority to AU2001274766A priority patent/AU2001274766A1/en
Priority to DE60124400T priority patent/DE60124400T2/de
Priority to US10/311,201 priority patent/US20030191177A1/en
Priority to IL15324501A priority patent/IL153245A0/xx
Priority to CN01811540A priority patent/CN1437484A/zh
Priority to RU2002133205/15A priority patent/RU2271802C2/ru
Priority to PL36048401A priority patent/PL360484A1/xx
Priority to HU0302371A priority patent/HUP0302371A3/hu
Priority to MXPA02012957A priority patent/MXPA02012957A/es
Priority to AT01941409T priority patent/ATE344675T1/de
Priority to CA002411100A priority patent/CA2411100A1/fr
Priority to JP2002503228A priority patent/JP2003535875A/ja
Priority to SK1807-2002A priority patent/SK18072002A3/sk
Priority to EEP200200703A priority patent/EE200200703A/xx
Priority to ES01941409T priority patent/ES2274892T3/es
Priority to BR0111790-4A priority patent/BR0111790A/pt
Priority to NZ523188A priority patent/NZ523188A/en
Priority to KR1020027017474A priority patent/KR20030010750A/ko
Priority to PCT/SE2001/001380 priority patent/WO2001097751A2/fr
Priority to CZ20024181A priority patent/CZ20024181A3/cs
Priority to ZA200209908A priority patent/ZA200209908B/en
Priority to BG107373A priority patent/BG107373A/bg
Priority to IS6653A priority patent/IS6653A/is
Priority to NO20026177A priority patent/NO20026177L/no
Priority to HK03106811.1A priority patent/HK1054508A1/zh
Priority to US11/407,505 priority patent/US20060252814A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
SE0002354A 2000-06-22 2000-06-22 New formulation SE0002354D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE0002354A SE0002354D0 (sv) 2000-06-22 2000-06-22 New formulation
ARP010102759A AR028699A1 (es) 2000-06-22 2001-06-11 Nueva formulacion
CZ20024181A CZ20024181A3 (cs) 2000-06-22 2001-06-15 Farmaceutické prostředky obsahující betablokátor
AT01941409T ATE344675T1 (de) 2000-06-22 2001-06-15 Verwendung eines betablockers zur behandlung von atherosklerose
SK1807-2002A SK18072002A3 (sk) 2000-06-22 2001-06-15 Farmaceutické prípravky obsahujúce betablokátor a ich použitie
DE60124400T DE60124400T2 (de) 2000-06-22 2001-06-15 Verwendung eines betablockers zur behandlung von atherosklerose
US10/311,201 US20030191177A1 (en) 2000-06-22 2001-06-15 Fomulation
IL15324501A IL153245A0 (en) 2000-06-22 2001-06-15 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
CN01811540A CN1437484A (zh) 2000-06-22 2001-06-15 含有β－受体阻滞剂和任选的降胆固醇剂的新型制剂
RU2002133205/15A RU2271802C2 (ru) 2000-06-22 2001-06-15 Применение фармацевтического препарата, содержащего бета-блокатор
PL36048401A PL360484A1 (en) 2000-06-22 2001-06-15 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
HU0302371A HUP0302371A3 (en) 2000-06-22 2001-06-15 New pharmaceutical composition comprising a betablocker and optionally a cholesterol-lowering agent
MXPA02012957A MXPA02012957A (es) 2000-06-22 2001-06-15 Formulacion nueva.
EP01941409A EP1296716B1 (fr) 2000-06-22 2001-06-15 Utilisation d'un beta-bloquant pour le traitement de l'atherosclerose
CA002411100A CA2411100A1 (fr) 2000-06-22 2001-06-15 Nouvelle formulation
JP2002503228A JP2003535875A (ja) 2000-06-22 2001-06-15 新規製剤
AU2001274766A AU2001274766A1 (en) 2000-06-22 2001-06-15 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
EEP200200703A EE200200703A (et) 2000-06-22 2001-06-15 Beeta-blokaatorit ja vajadusel kolesterooli alandavat ainet sisaldav uus ravimvorm
ES01941409T ES2274892T3 (es) 2000-06-22 2001-06-15 Uso de un betabloqueante para el tratamiento de aterosclerosis.
BR0111790-4A BR0111790A (pt) 2000-06-22 2001-06-15 Formulação farmacêutica, método para tratamento profilático ou terapêutico de um paciente sofrendo ou suscetìvel de sofrer de aterosclerose, uso de uma formulação farmacêutica, e, kit de partes
NZ523188A NZ523188A (en) 2000-06-22 2001-06-15 Use of a betablocker in the manufacture of a medicament to treat artherosclerosis
KR1020027017474A KR20030010750A (ko) 2000-06-22 2001-06-15 베타블록커 및 임의로 콜레스테롤 저하제를 포함하는신규한 제제
PCT/SE2001/001380 WO2001097751A2 (fr) 2000-06-22 2001-06-15 Nouvelle formulation
ZA200209908A ZA200209908B (en) 2000-06-22 2002-12-05 New formulation comprising a betablocker and optionally a cholesterol-lowering agent.
BG107373A BG107373A (bg) 2000-06-22 2002-12-11 Нов състав, съдържащ бета-блокер и евентуално средство, понижаващо холестерола
IS6653A IS6653A (is) 2000-06-22 2002-12-11 Ný blanda sem felur í sér betatálma og mögulega kólesteróllækkandi efni
NO20026177A NO20026177L (no) 2000-06-22 2002-12-20 Ny formulering omfattende en betablokker og eventuelt et kolesterolreduserende middel
HK03106811.1A HK1054508A1 (zh) 2000-06-22 2003-09-22 新型製劑
US11/407,505 US20060252814A1 (en) 2000-06-22 2006-04-19 Formulation comprising a betablocker and optionally a cholestrol-lowering agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002354A SE0002354D0 (sv) 2000-06-22 2000-06-22 New formulation

Publications (1)

Publication Number Publication Date
SE0002354D0 true SE0002354D0 (sv) 2000-06-22

Family

ID=20280209

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002354A SE0002354D0 (sv) 2000-06-22 2000-06-22 New formulation

Country Status (28)

Country Link
US (2) US20030191177A1 (fr)
EP (1) EP1296716B1 (fr)
JP (1) JP2003535875A (fr)
KR (1) KR20030010750A (fr)
CN (1) CN1437484A (fr)
AR (1) AR028699A1 (fr)
AT (1) ATE344675T1 (fr)
AU (1) AU2001274766A1 (fr)
BG (1) BG107373A (fr)
BR (1) BR0111790A (fr)
CA (1) CA2411100A1 (fr)
CZ (1) CZ20024181A3 (fr)
DE (1) DE60124400T2 (fr)
EE (1) EE200200703A (fr)
ES (1) ES2274892T3 (fr)
HK (1) HK1054508A1 (fr)
HU (1) HUP0302371A3 (fr)
IL (1) IL153245A0 (fr)
IS (1) IS6653A (fr)
MX (1) MXPA02012957A (fr)
NO (1) NO20026177L (fr)
NZ (1) NZ523188A (fr)
PL (1) PL360484A1 (fr)
RU (1) RU2271802C2 (fr)
SE (1) SE0002354D0 (fr)
SK (1) SK18072002A3 (fr)
WO (1) WO2001097751A2 (fr)
ZA (1) ZA200209908B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053683A1 (fr) 2003-11-26 2005-06-16 Duke University Technique de prevention ou de traitement du glaucome
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100836321B1 (ko) 2006-10-31 2008-06-09 현대자동차주식회사 차량용 모니터 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
EP0576617B1 (fr) * 1991-03-18 1996-08-07 Sepracor, Inc. Composition et procede contenant du metoprolol optiquement pur (s)
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
AU779264B2 (en) * 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications

Also Published As

Publication number Publication date
US20060252814A1 (en) 2006-11-09
WO2001097751A3 (fr) 2002-03-28
CZ20024181A3 (cs) 2003-04-16
DE60124400T2 (de) 2007-10-31
US20030191177A1 (en) 2003-10-09
JP2003535875A (ja) 2003-12-02
IL153245A0 (en) 2003-07-06
NZ523188A (en) 2006-06-30
SK18072002A3 (sk) 2003-08-05
BG107373A (bg) 2003-09-30
CA2411100A1 (fr) 2001-12-27
EE200200703A (et) 2004-08-16
NO20026177D0 (no) 2002-12-20
IS6653A (is) 2002-12-11
ATE344675T1 (de) 2006-11-15
ES2274892T3 (es) 2007-06-01
HK1054508A1 (zh) 2003-12-05
KR20030010750A (ko) 2003-02-05
MXPA02012957A (es) 2003-05-15
AR028699A1 (es) 2003-05-21
ZA200209908B (en) 2004-03-05
PL360484A1 (en) 2004-09-06
DE60124400D1 (de) 2006-12-21
WO2001097751A2 (fr) 2001-12-27
CN1437484A (zh) 2003-08-20
HUP0302371A2 (hu) 2003-11-28
NO20026177L (no) 2002-12-20
BR0111790A (pt) 2003-05-20
HUP0302371A3 (en) 2007-03-28
RU2271802C2 (ru) 2006-03-20
EP1296716A2 (fr) 2003-04-02
EP1296716B1 (fr) 2006-11-08
AU2001274766A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
PT1412384E (pt) Formulação estável de glp-1 modificado
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL309721A1 (en) Pharmaceutical composition containing fluoxetin hydrochloride
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
DE602004011966D1 (en) Heterocyclylverbindungen
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0102440D0 (sv) New compound
MXPA02009705A (es) Nueva combinacion de un betabloqueador y un agente de disminucion de colesterol.
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0001916D0 (sv) Novel formulation
SE0002354D0 (sv) New formulation
SE9800905L (sv) Ny terapi vid glomerulonefrit
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.